Berlanga 1999.
| Study characteristics | ||
| Study details |
Sponsorship source: Not reported Country: Mexico Setting: Secondary care (outpatients) Year of recruitment: 1994 ‐ 1996 Author's contact details: Mexican Institute of Psychiatry, Avenue México‐Xochimilco 101 Colonia San Lorenzo Huipulco, Tlalpan, Mexico D.F. 14370 (e‐mail: cisnerb@lmp.edu.mx) |
|
| Methods |
Type of study: Model development study Source of data: Post‐RCT* prospective follow‐up study Method used for model development: Logistic regression (multivariable analysis with a stepwise backward method in which variables that were significant in the univariable analysis were introduced into the model) Method used for internal validation: Not reported External validation: Not done Handling of missing data: Not reported Evaluation of clinical utility: Not assessed |
|
| Sample size |
Total number of participants (Number with event): 42 (18) Number of candidate predictor parameters: Not reported Number of predictors in final model: 3 Number of events per candidate predictor parameter (EPP): Unclear |
|
| Population |
Inclusion criteria:
Exclusion criteria:
|
|
| Baseline characteristics |
Mean age (SD): Recurrence group: 34.8 (11.1); No‐recurrence group: 37.2 (11.2) Gender (% Female): Recurrence group: 83; No‐recurrence group: 71 |
|
| Start‐point (diagnosis of depression and remission) |
Depression: Major depressive disorder according to DSM‐IV criteria and at least 18 points on the first 17 items of the 21‐item HAM‐D Remission: Definition of remission not reported |
|
| End‐point (diagnosis of relapse/recurrence) | Recurrence: Fulfilling criteria for MDD (clinical interview) per Frank 1991 | |
| Timing (length of follow‐up) | 12 months | |
| Notes | *The RCT compared the clinical efficacy and tolerance of the antidepressants nefazodone and fluoxetine. A 'washout period' of at least 3 weeks free of antidepressant medication was a requisite for all participants | |